Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials

BACKGROUND: Baricitinib, a selective Janus kinase 1/Janus kinase 2 inhibitor, is indicated in the European Union and Japan for the treatment of moderate-to-severe atopic dermatitis (AD) in adults who are candidates for systemic therapy. OBJECTIVE: The objective of this study was to evaluate the safe...

Descripción completa

Detalles Bibliográficos
Autores principales: King, Brett, Maari, Catherine, Lain, Edward, Silverberg, Jonathan I., Issa, Maher, Holzwarth, Katrin, Brinker, Dennis, Cardillo, Tracy, Nunes, Fabio P., Simpson, Eric L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8068648/
https://www.ncbi.nlm.nih.gov/pubmed/33826132
http://dx.doi.org/10.1007/s40257-021-00602-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8068648/
https://www.ncbi.nlm.nih.gov/pubmed/33826132
http://dx.doi.org/10.1007/s40257-021-00602-x

Ejemplares similares